TerminatedPhase 1/2

Transcranial Ultrasound in Clinical SONothrombolysis

Stopped: Sponsor decision

United States72 participantsStarted 2006-12

Plain-language summary

This is a randomized, placebo controlled, parallel group dose escalation trial to evaluate the safety, tolerability, and activity of four sequential dose tiers of MRX-801 and ultrasound as an adjunctive therapy to tissue plasminogen activator (tPA) treatment in subjects with acute ischemic stroke.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Acute ischemic stroke * Occlusion demonstrated by transcranial Doppler ultrasound * Eligible for tPA Exclusion Criteria: * Right to left cardiac shunt * Moderate to severe COPD * Uncontrolled hypertension

What they're measuring

Incidence of symptomatic intracranial hemorrhage

Timeframe: 36 hours

Trial details

NCT IDNCT00504842

SponsorImaRx Therapeutics

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

View on ClinicalTrials.gov More Acute Ischemic Stroke trials